A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Patients with refractory or relapsed hematologic malignancies will receive CP-4055
intravenously(IV) on Day 1-5 every three weeks until complete response or disease
worsening/progressing